SquareOne is a venture capital firm focused on pre-seed and seed investments in B2B technology. Typically the first institutional investor on the cap table, SquareOne provides a unique first-customers-guarantee to all its portfolio companies, acting as an entrepreneurial sparring partner and hands-on supporter from day one. With its network of leading executives, tech entrepreneurs, and investors, SquareOne builds the foundation for large and profitable category leaders in B2B software and deep tech businesses across Europe and counts companies like Stripe, Pipedrive, Carbon One, and Wandelbots as part of its portfolio. The Berlin-based VC, formerly known as Paua Ventures, was founded in 2010.

SquareOne Venture Capital

Speedinvest is one of Europe’s most active early-stage investors, with more than €1bn AUM, 40 investors, and offices in Berlin, London, Munich, Paris, Vienna and San Francisco.  Your success is our priority, so we don’t just send some money and ''check in'' at board meetings. Our mission is to empower you with game-changing support through every stage of your journey.  Our focused investment teams know your industry inside and out. Their Deep Tech, Fintech, Industrial Tech, Network Effects, Digital Health and Subscriptions experience, know-how and deep networks are yours from day one.  You also have full access to our in-house Platform+ team of operational experts who can provide tailored growth marketing, people (HR), US business development, and networking support throughout every stage of your journey.

Speedinvest

The best early stage operators are entrepreneurs at heart. We are a talent platform connecting them with breakout jobs, potential cofounders and early investors depending on where they stand in their founder journey. Join us on our mission to democratize entrepreneurship by bringing the best of YC, Reforge and AngelList to Europe.

bldrs

Cherry Ventures is an early-stage venture capital firm led by a team of entrepreneurs with experience building fast-scaling companies such as Zalando and Spotify. The firm backs Europe's boldest founders, usually as their first institutional investor, and supports them in everything from their go-to-market strategy and the scaling of their businesses. Cherry Ventures has previously invested in the seed stage of over 50 companies across Europe, including FlixBus, Auto1 Group, Infarm, Rows, Forto, and TourRadar. Cherry Ventures is based in Berlin and invests across Europe with operations in London, Paris, and Stockholm.

Cherry Ventures

LUMUS is an initiative that educates, supports, and connects female Angel Investors to investment opportunities.

LUMUS Investment Collective

Flinn

Our vision is to make high-quality health products accessible for everyone. We will achieve this by enabling creators of health products to build and operate high-quality products with 10x efficiency.  We are putting our initial focus on automating compliance and regulatory tasks for medical device manufacturers. Our product offering includes AI-enabled automation of major parts of the data collection, aggregation, evaluation, and reporting for post-market surveillance activities.

Vienna-based Flinn’s software platform is designed to streamline quality management for regulatory affairs, particularly targeting mid-sized companies in Europe. The company claims its SaaS-based solutions enable medical device manufacturers to make their compliance processes 10x more efficient by integrating AI-powered automation into data processing, evaluation, and reporting.

Flinn Comply: Startup ehemaliger N26-Mitarbeiter holt 1,8 Mio. Euro Pre-Seed

Flinn Comply

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Flinn Comply is a Software as a Service (SaaS) provider specializing in automating compliance processes for medical device manufacturers. The company's primary focus is to help businesses navigate the complex requirements of the European Union's Medical Device Regulation (MDR), which was implemented in 2020. Flinn Comply's software platform is designed to streamline quality management for regulatory affairs, particularly targeting mid-sized companies in Europe. The company aims to address the challenges posed by the MDR, which has made it more difficult, time-consuming, and expensive for MedTech products to enter the market. Flinn Comply's initial product development is centered on AI-supported automation of crucial aspects of data collection, analysis, and reporting. The long-term vision is to create a comprehensive software platform that enables companies to manage all regulatory requirements related to their medical devices.
Key customers and partnerships
Flinn Comply's target customers were primarily mid-sized companies in Europe operating in the medical technology sector. The company aimed to assist these businesses in meeting the stringent MDR requirements more effectively through its quality management software for regulatory affairs.

Vienna-based Flinn’s software platform is designed to streamline quality management for regulatory affairs, particularly targeting mid-sized companies in Europe. The company claims its SaaS-based solutions enable medical device manufacturers to make their compliance processes 10x more efficient by integrating AI-powered automation into data processing, evaluation, and reporting.Flinn.ai's product portfolio includes AI-driven modules for quality management and regulatory compliance, with a focus on post-market surveillance automation. These solutions aim to help MedTech manufacturers navigate the increasing complexity of regulatory requirements, particularly in light of the EU Medical Device Regulation, which has led to significant increases in compliance costs for many companies.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

<div>
 
 Flinn.ai, a medical device compliance software provider, received EUR 10 million (~USD 11 million) in investment from Cherry Ventures, Speedinvest, SquareOne and various business angels, including Matthias Weber and Michael Reitermann.
 The funds will be used to speed up market and product expansion, with a specific goal of improving its AI-driven modules for quality management and regulatory compliance.
 Based in Vienna, Flinn’s software platform targets mid-sized European companies, aiming to optimise regulation management. By incorporating AI technology into data processing, evaluation, and reporting, the company's SaaS solutions help manufacturers enhance the efficiency of their compliance processes.
 
</div>

Flinn Comply

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless